Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Nuwellis, Inc. (Nasdaq: NUWE), a medical technology and medical device company focused on precision fluid management for patients with cardio-renal conditions and fluid overload. Through these filings, investors can review how Nuwellis reports its financial performance, material events, and key developments related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Current report filings (Form 8-K) for Nuwellis often cover topics such as quarterly financial results, changes in executive roles, new patents, NIH grant-supported programs, FDA 510(k) clearances for accessories like catheters, and at-the-market equity offering agreements. Some 8-K filings also reference press releases announcing clinical registry findings, such as the ULTRA-Peds pediatric Aquadex registry, or new intellectual property supporting pediatric safety features and hemolysis sensing in extracorporeal circuits.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide more detailed discussions of Nuwellis’ business, including its focus on fluid overload, its Aquadex SmartFlow system, development-stage technologies like Vivian, and its geographic footprint with headquarters in Minneapolis and a subsidiary in Ireland. These filings also describe risk factors, liquidity, capital-raising activities, and other information relevant to NUWE shareholders.
Stock Titan’s platform enhances these SEC documents with AI-powered summaries that explain the key points of lengthy filings, highlight important changes from prior periods, and help users quickly understand complex disclosures. Investors can also use this page to follow real-time updates as new Nuwellis filings are posted to EDGAR, including current reports, registration statements, and other material submissions related to NUWE.
Nuwellis, Inc. reported that director Gregory D. Waller received a grant of 6,744 nonstatutory stock options for common stock. The options have an exercise price of $1.16 per share and expire on April 27, 2036.
According to the filing, these options vest in 12 approximately equal monthly installments starting one month after the grant date, becoming fully vested after one year. Following this award, Waller holds 6,744 derivative securities of this type directly, reflecting a routine compensation-related equity grant rather than an open-market purchase.
Nuwellis, Inc. director Emerson J. Martin received a grant of nonstatutory stock options as part of his equity compensation. The award covers 6,744 options to buy Nuwellis common stock at an exercise price of $1.16 per share.
The options vest in 12 approximately equal monthly installments starting one month after the grant date, so they are fully vested after one year. The options expire on April 27, 2036 if not exercised. After this grant, Martin holds 6,744 derivative securities related to Nuwellis common stock directly.
Nuwellis, Inc. director Archelle Georgiou Feldshon received a grant of nonstatutory stock options covering 6,744 shares of common stock. The options have an exercise price of $1.16 per share and expire on April 27, 2036.
The award vests in 12 approximately equal monthly installments starting one month after the grant date, so all 6,744 options will be fully vested on the one-year anniversary of the grant. This is a compensation-related equity grant, not an open-market share purchase or sale.
Nuwellis, Inc. director David McDonald received a grant of nonstatutory stock options covering 6,744 shares of common stock. The options have an exercise price of $1.16 per share and expire on April 27, 2036. They vest in 12 approximately equal monthly installments over one year.
Nuwellis, Inc. held its annual stockholder meeting where investors elected two Class I directors and approved the company’s auditor for 2026. Marty J. Emerson and David A. McDonald were elected to three-year terms ending at the 2029 annual meeting.
Stockholders also ratified Baker Tilly US, LLP as Nuwellis’ independent registered public accounting firm for the fiscal year ending December 31, 2026. A total of 1,078,020 common shares, representing approximately 43.81% of shares outstanding as of the record date, were represented virtually or by proxy.
Nuwellis, Inc. has settled a contract dispute with E.F. Hutton & Co. over an engagement letter related to registered securities offerings. Under a Settlement Agreement and Release dated April 24, 2026, Nuwellis agreed to pay $204,000 to Hutton within five days.
The agreement includes no admission of liability, mutual releases of all claims, and an obligation for Hutton to file a stipulation to dismiss the lawsuit with prejudice within two days after receiving the settlement payment.
Nuwellis, Inc. is asking stockholders to vote at its 2026 annual meeting, to be held virtually on April 28, 2026 at 2:00 p.m. U.S. Central Time. Holders of common stock at the March 24, 2026 record date, when 2,635,718 shares were outstanding, may participate and vote.
Stockholders are being asked to elect two Class I directors, Martin Emerson and David McDonald, to terms running to the 2029 meeting, and to approve on an advisory basis the appointment of Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR the auditor ratification.
Nuwellis, Inc. filed an amended current report to update an earlier disclosure about board resignations. This Amendment No. 1 adds as exhibits supplemental response letters from former directors Katharyn Field and Mika Grasso addressing the company’s initial description of their March 26, 2026 resignations.
The company states it does not agree with certain statements in these response letters and maintains that its original account in the initial filing is accurate. Nuwellis emphasizes that the resignation and response letters reflect only the former directors’ personal views and may conflict with management’s and the board’s views.
The company cautions that it does not take responsibility for the contents of the former directors’ letters and encourages stockholders and investors to rely on information in its official SEC reports, including its most recent annual and quarterly reports.